Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025British Journal of HaematologyOpen Access

Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLydia MontesSCSylvain ChoquetMUMadalina Uzunov

Discussion

Loading...

Member takes

Overview

Retrospective analysis of ASCT and CAR T-cell therapy shows improved outcomes in CNS lymphoma patients, suggesting a potential new treatment approach.

Key Points

  • Combination of ASCT and CAR T-cell therapy resulted in complete responses for four out of five patients with CNS lymphomas.
  • One-year progression-free survival rate after the combination was significantly higher than CAR T-cell therapy alone, with patients remaining disease-free.
  • Analysis of treatment outcomes utilized a retrospective observational approach, focusing on patient data from a specialized network for CNS lymphomas.
  • These findings highlight a promising treatment strategy, though larger studies are required for validation and to assess long-term safety.

Cite This Study

Montes et al. (2025) studied this question.

synapsesocial.com/papers/68c23966b210217d6477c4bahttps://doi.org/10.1111/bjh.70132
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy2025
  2. 2Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  3. 3Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  4. 4P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  5. 5Outcomes in patients with refractory/relapsed CNS lymphoma treated in complete remission：autologous transplantation vs. CAR-T therapy2025